A Perspective on the Evolving story of PSMA Biology and PSMA Based Imaging and Endoradiotherapeutic Strategies.

We will review the evolution of knowledge of the biology of Prostate-Specific Membrane Antigen (PSMA) and how the translation to therapy has also developed. The usual key to discovery is a realistic model for experimentation and hypothesis testing. This is especially true for the prostate where the human prostate differs significantly from that of other often used species for research models. We will emphasize the genetic characterization of PSMA, The nature of the PSMA protein and its role as a carboxypeptidase, with differing important substrates and products in different tissues. We will give special prominence to its importance as a target for imaging and therapy in prostate cancer and its under-developed role for imaging and targeting the neovasculature of tumors other than prostate cancer. Lastly we will bring attention to its importance in other non-prostatic tissues

[1]  U. Haberkorn,et al.  Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control , 2018, The Journal of Nuclear Medicine.

[2]  H. Hieronymus,et al.  Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors , 2018, The Journal of experimental medicine.

[3]  U. Haberkorn,et al.  Glu-Ureido–Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers , 2017, The Journal of Nuclear Medicine.

[4]  Steven P Rowe,et al.  Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy , 2017, The Journal of Nuclear Medicine.

[5]  J. Konvalinka,et al.  Mouse glutamate carboxypeptidase II (GCPII) has a similar enzyme activity and inhibition profile but a different tissue distribution to human GCPII , 2017, FEBS open bio.

[6]  J. Czernin,et al.  Acceleration of PSMA-Targeted Theranostics to the Clinic: Can Common Sense Prevail? , 2017, The Journal of Nuclear Medicine.

[7]  K. Rahbar,et al.  177Lu-PSMA Radioligand Therapy for Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[8]  B. Slusher,et al.  Still NAAG'ing After All These Years: The Continuing Pursuit of GCPII Inhibitors. , 2016, Advances in pharmacology.

[9]  Danny F. Martinez,et al.  First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake , 2016, The Journal of Nuclear Medicine.

[10]  M. Brunelli,et al.  Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells “in vitro” and correlating with progression “in vivo” , 2016, Oncotarget.

[11]  M. Marohn,et al.  FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities. , 2016, JCI insight.

[12]  M. Ghosh,et al.  Prostate-specific membrane antigen (PSMA)-mediated laminin proteolysis generates a pro-angiogenic peptide , 2016, Angiogenesis.

[13]  K. Pienta,et al.  PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges , 2016, Prostate Cancer and Prostatic Disease.

[14]  Jennifer L. Gregg,et al.  MP66-19 PROSTATE-SPECIFIC MEMBRANE ANTIGEN INTERACTS WITH DIETARY FOLATE TO FACILITATE PROSTATE CARCINOGENESIS AND PROGRESSION , 2016 .

[15]  R. Baum,et al.  177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy , 2016, The Journal of Nuclear Medicine.

[16]  Amanda C. Freise,et al.  In vivo imaging with antibodies and engineered fragments. , 2015, Molecular immunology.

[17]  S. Larson,et al.  Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors , 2015, EJNMMI Research.

[18]  F. Difilippo,et al.  Improving the biodistribution of PSMA‐targeting tracers with a highly negatively charged linker , 2014, The Prostate.

[19]  B. Hadaschik,et al.  Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  D. O’Keefe,et al.  Opposing roles of folate in prostate cancer. , 2013, Urology.

[21]  G. Tisman,et al.  Control of prostate cancer associated with withdrawal of a supplement containing folic acid, L-methyltetrahydrofolate and vitamin B12: a case report , 2011, Journal of medical case reports.

[22]  F. Bowman,et al.  Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. , 2011, Radiology.

[23]  Sarat Chandarlapaty,et al.  Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. , 2011, Cancer cell.

[24]  D. O’Keefe,et al.  Expression of prostate‐specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non‐polyglutamated folate, folic acid , 2010, The Prostate.

[25]  J. Baron,et al.  Folic acid and risk of prostate cancer: results from a randomized clinical trial. , 2009, Journal of the National Cancer Institute.

[26]  A. Parwani,et al.  Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis. , 2008, Cancer Research.

[27]  N. Rao,et al.  Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability , 2008, Molecular Cancer Therapeutics.

[28]  Elizabeth L. Barry,et al.  Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. , 2007, JAMA.

[29]  Simon A. Williams,et al.  Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and human , 2006, The Prostate.

[30]  N. Callizot,et al.  Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury , 2005, Journal of neurochemistry.

[31]  A. Rajasekaran,et al.  Is prostate-specific membrane antigen a multifunctional protein? , 2005, American journal of physiology. Cell physiology.

[32]  Mindy I. Davis,et al.  Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Konvalinka,et al.  Identification of the N‐glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity , 2004, Protein science : a publication of the Protein Society.

[34]  D. O’Keefe,et al.  Comparative analysis of prostate‐specific membrane antigen (PSMA) versus a prostate‐specific membrane antigen‐like gene , 2004, The Prostate.

[35]  Prabhjot Kaur,et al.  Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  W. Heston,et al.  Effect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigen , 2003, The Prostate.

[37]  J. Neale,et al.  Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N‐acetylaspartylglutamate , 2002, Journal of neurochemistry.

[38]  F. Watt,et al.  A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1. , 2001, Genomics.

[39]  D. S. Coffey.  Similarities of prostate and breast cancer: Evolution, diet, and estrogens. , 2001, Urology.

[40]  W. Tong,et al.  Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase , 2001, Mammalian Genome.

[41]  A. Uchida,et al.  Prostate‐specific suicide gene therapy using the prostate‐specific membrane antigen promoter and enhancer , 2000, The Prostate.

[42]  R L Sokoloff,et al.  A dual‐monoclonal sandwich assay for prostate‐specific membrane antigen: Levels in tissues, seminal fluid and urine , 2000, The Prostate.

[43]  V. Reuter,et al.  Prostate-specific membrane antigen is produced in tumor-associated neovasculature. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  N. Nowak,et al.  Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. , 1998, Biochimica et biophysica acta.

[45]  N. Bander,et al.  Constitutive and antibody-induced internalization of prostate-specific membrane antigen. , 1998, Cancer research.

[46]  N. Rawlings,et al.  Structure of membrane glutamate carboxypeptidase. , 1997, Biochimica et biophysica acta.

[47]  George L. Wright,et al.  Location of prostate‐specific membrane antigen in the LNCaP prostate carcinoma cell line , 1997, The Prostate.

[48]  B. Suffoletto,et al.  Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  W. Fair,et al.  Expression of the prostate-specific membrane antigen. , 1994, Cancer research.

[50]  W. Fair,et al.  Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. , 1993, Cancer research.

[51]  G. Murphy,et al.  LNCaP model of human prostatic carcinoma. , 1983, Cancer research.

[52]  Kratochwil Clemens,et al.  Targeted Alpha Therapy of mCRPC with 225Actinium-PSMA-617: Dosimetry estimate and empirical dose finding , 2017 .

[53]  Steven P Rowe,et al.  PSMA-Targeted 18F-DCFPyL PET/CT Imaging of Clear Cell Renal Cell Carcinoma: Results from a Rapid Autopsy. , 2017, European urology.

[54]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  P. Schellhammer,et al.  Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. , 1995, Urologic oncology.

[56]  G. Murphy,et al.  Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. , 1987, Anticancer research.